Ophthalmology

Intravitreal anti-VEGF use not tied to systemic adverse events

(HealthDay)—Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment is not associated with increased risk of systemic adverse events for patients with neovascular age-related macular degeneration, diabetic ...

Medications

Aflibercept in macular oedema after BRVO: No hint of added benefit

Since February 2015, aflibercept (trade name Eylea) has been available also for patients with impaired vision due to macular oedema that follows blockage of branch veins of the central retinal vein (branch retinal vein occlusion, ...

Ophthalmology

Young scientist helps identify cause of widespread eye disease

Branch retinal vein occlusion – blockage of the blood vessels that channel blood from the retina – is a common eye disease. A type of blood clot in the eye, the disease causes reduced vision, and people with the disease ...

page 1 from 2